Search published articles
Showing 3 results for Monotherapy
Hosein Dostkamy, Raeouf Mollajavad , Ahad Azami ,
Volume 7, Issue 2 (6-2007)
Background & objectives: Hypertension is a disease with high prevalence and complications and unfortunately the freatment of which is not desirable in many communities including ours. The aim of this study is to assess the therapeutic diet giving and level control of HTN in patients with Hypertension who refered to Ardabil Boali Hospital emergency room and out patient Clinic room.
Methods: This study was performed on 200 patients who refered to the emergency room and out patient Clinic in Ardabil Boali Hospital from 2003 to 2004 due to high blood pressure. In this study, blood pressure and other factors such as sex, age and the therapeutic modality including compliance to theyapy and kind and quality of drugs were determined, then the data was analyzed by using descriptive statistics.
Results: Of 200 patients only 1% did not take drug 59.5% of patients were on monotherapy and 39.5% took two or more drugs 33.5% were on Beta blocker (Atenolol) and 11% on ACE inhibitor (Enalapril). Among patients on combination therapy the highest prevalence was B.bloche and ACE.I 40%, and the least one prevalence was diuretic and CCB (2%). All patients on diuretic were pre hypertensive whereas the majority of patients on CCB had stageII hypertension. In patients on multi drug therapy all patients on diuretics + CCB were pre hypertensive but 57% of patients on ACEI + CCB or ACE.I + diuretic had stageII hypertension.
Conclusion: In this study for combination therapy Diuretic and CCB had the best result in controlling hypertension.
Behzad Babapour, Farhad Pourfarzi, Mehdi Samadzadeh, Alireza Mohammadzadeh, Elham Atigi, Bita Shahbazzadegan,
Volume 13, Issue 3 (9-2013)
Background & Objectives: Hypertension is one of the most important and common health problems in societies. Hypertension is often asymptomatic and can be simply treated. Many of drugs are available for treatment of hypertension i ncluding d iuretics, beta blockers, blockers of calcium channel, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, alpha blockers and arterial dilators. This research was performed to evaluate the efficacy of some of these drugs on the hypertension. This may help to choose an appropriate medication for the treatment of stage 2 hypertension.
Methods: A total of 150 patients with hypertension who were not under antihypertensive treatment and didn’t have contraindications for using hydrochlorothiazide , enalapril and atenolol were randomly allocated into three groups. These groups received atenolol 50 mg daily, hydrochlorothiazide 50 mg daily and enalapril 5 mg twice daily, respectively . After three weeks blood pressure of patients was measured and results were analyzed using SPSS.
Results: Atenolol reduced systolic blood pressure (26.7±6.7 mm Hg 16.1%), diastolic blood pressure (10.3±1.2 mm Hg 10.4%) and mean arterial blood pressure (16.1±6.4 mm Hg 13.1%). Enalapril reduced systolic blood pressure (30.6±8.8 mm Hg 17.4%), diastolic blood pressure (11.5±4.4 mm Hg 11.4%) and mean arterial blood pressure (17.9±7.0 mm Hg 14.2%). Hydrochlorothiazide reduced systolic blood pressure (25.1±5.8 mm Hg 14.6%), diastolic blood pressure (9.2±2.3 mm Hg 9.3%) and mean arterial blood pressure (14.5±6.4 mm Hg 11.8%).
Conclusion: Despite recommendations the use of hydrochlorothiazidein the treatment of hypertension, seems lower effect only use of this drug groups in comparison with other groups, and maybe add this category to other drugs and combined treatment is better than monotherapy with these groups .
Hamdollah Panahpour, Mohammad Nouri, Mohammadghasem Golmohammadi, Nooshin Sadeghian ,
Volume 16, Issue 2 (7-2016)
Background & objectives: Stroke is third leading cause of death and disability in the most of human communities. Several experimental studies have shown that combination therapy with drugs that act via different mechanisms can produce amplified protective effects. We examined the effects of combination therapy with candesartan and alpha tocopherol against cerebral ischemia.
Methods: Male Sprague-Dawley rats were divided into five groups (n=24): sham, control ischemic, candesartan treated (0.3 mg/kg), alpha tocopherol treated (30 mg/kg) and combined treated ischemic groups. Transient focal cerebral ischemia was induced by 90-min-long occlusion of the left middle cerebral artery followed by 24-h-long reperfusion. Neurological deficit score was evaluated at the end of the reperfusion period. Thereafter, the animals were randomly used for measurement of the infarct volumes and investigation of ischemic brain edema formation using a wet/dry method.
Results: Induction of cerebral ischemia produced considerable brain infarction in conjunction with severely impaired motor functions and edema formation. Combined treatment with candesartan and alpha tocopherol significantly reduced the infarct volume and lowered the water content in the ischemic lesioned hemisphere. These effects on brain edema and oxidative stress biomarkers were significantly more than the monotherapy with candesartan.
Conclusion: The combination therapy with candesartan and alpha tocopherol can noticeably decrease ischemic brain injury and attenuate edema formation likely via increasing the antioxidant activity.